Our vision: individualize cancer medicine
Overview
In this section you can find all materials related to our financial reporting
Latest Annual Report (20-F)
We have not yet filed an Annual Report on Form 20-F.
Latest Annual Report (German)
Here you will find our latest German annual report going forward once we have filed our first report in 2020
Latest Quarterly Report
Show all2019
Q3
- Q3 2019 Financial Report 329.1 KB
- Finanzbericht 3. Quartal 2019 347.3 KB
- Q3 2019 Presentation 1.7 MB
Latest SEC Filings
| Filing date | Description | Form | View |
|---|---|---|---|
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | View HTML |
IR Side Nav
Toolkit
Media Contact Jasmina Alatovic
Senior Manager Global External Communications
Media@biontech.de
+49 6131 9084-1513
Senior Manager Global External Communications
Media@biontech.de
+49 6131 9084-1513
Investor Contact Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Investors@biontech.de
+49 6131 9084-074
VP Investor Relations & Business Strategy
Investors@biontech.de
+49 6131 9084-074
For U.S. Investors:
Westwicke
Victoria Meissner, M.D.
+1 646 677-1837
Westwicke
Victoria Meissner, M.D.
+1 646 677-1837
Whistleblower Hotline BioNTech Hotline (anonymous)
Germany: 0800 000-8972
US: 844 901-0271
Other: +1 757 278-0107
Online Access to Whistle Blowing Reporting
Or by Email
Germany: 0800 000-8972
US: 844 901-0271
Other: +1 757 278-0107
Online Access to Whistle Blowing Reporting
Or by Email
